The FDA granted fast-track status to RadioMedix and Curium's Cu-64 DOTATATE, a PET tracer for diagnosing neuroendocrine tumors. A late-stage trial for the agent has been completed, and a new drug application is expected to be submitted to the FDA this year.
PET tracer from RadioMedix, Curium gets FDA fast-track status
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.